Report : Europe Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)
At 5.0% CAGR, Europe Sarcopenia Treatment Market is Projected to be Worth US$ 1,467.81 Million by 2030, says Business Market Insights
According to Business Market Insights’ research, the Europe sarcopenia treatment market was valued at US$ 993.46 million in 2022 and is expected to reach US$ 1,467.81 million by 2030, registering a CAGR of 5.0% from 2022 to 2030. Products in clinical trial phases and rising awareness about sarcopenia are among the critical factors attributed to drive the Europe sarcopenia treatment market growth.
A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:
Sarcopenia Drug Under Clinical Development
Company Name | Interventions | Conditions | Clinical Trial Stage |
Abbott Nutrition | Medical Food with AN777 Oral Nutritional Formula | Malnutrition Sarcopenia | PHASE3 |
Nutricia Research | Dietary Supplement: Bolus ONS A Dietary Supplement: Bolus ONS B Dietary Supplement: Bolus ONS C Dietary Supplement: Bolus ONS D | Sarcopenia | PHASE1 |
Novartis Pharmaceuticals | Drug: Bimagrumab | Sarcopenia | PHASE2 |
McMaster University | Behavioural: Step Reduction | Sarcopenia | PHASE1 |
Metabolic Technologies Inc. | Dietary Supplement: Placebo Drug: HMB Plus Vitamin D Behavioural: Non-Exercise Behavioural: Exercise | Sarcopenia | PHASE1 |
Merck Sharp & Dohme LLC | Drug: Comparator MK-077 Drug: Comparator Placebo | Sarcopenia | PHASE2 |
Immunotec Inc. | Dietary Supplement: Immunocal Dietary Supplement: Casein | Aging and Sarcopenia | PHASE2 |
Lijun Yang | Combination Product: 3-Month Intensive Intervention | Sarcopenia | PHASE4 |
Regeneron Pharmaceuticals | Drug: REGN1033 (SAR391786) Drug: Placebo | Sarcopenia | PHASE2 |
Source: Company Websites and Business Market Insights Analysis
Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.
On the contrary, unavailability of direct interventions hampers the growth of Europe sarcopenia treatment market.
Based on treatment type, the Europe sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held 41.5% share of Europe sarcopenia treatment market in 2022, amassing US$ 412.46 million. It is projected to garner US$ 650.67 million by 2030 to register 5.9% CAGR during 2022–2030.
In terms of distribution channel, the Europe sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held 39.4% share of Europe sarcopenia treatment market in 2022, amassing US$ 391.20 million. It is anticipated to garner US$ 555.67 million by 2030 to expand at 4.5% CAGR during 2022–2030.
Based on country, the Europe sarcopenia treatment market is categorized into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 28.1% share of Europe sarcopenia treatment market in 2022. It was assessed at US$ 279.26 million in 2022 and is likely to hit US$ 431.39 million by 2030, registering a CAGR of 5.6% during 2022–2030.
Key players operating in the Europe sarcopenia treatment market are Abbott Laboratories, Amway Corp, Bayer AG, GSK Plc, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, and Sanofi SA, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com